Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Login and Edit functionaility are currrently unavailable.

Hiroaki Wakimoto, Ph.D., M.D.


The research activities and funding listed below are automatically derived from NIH ExPORTER and other sources, which might result in incorrect or missing items. Faculty can login to make corrections and additions.
  1. R01CA227821 (CAHILL, DANIEL P) Mar 15, 2018 - Feb 28, 2023
    Targeting Nicotinamide Adenine Dinucleotide (NAD+) metabolism in IDH mutant gliomas
    Role: Co-Principal Investigator
  2. R21NS103187 (WAKIMOTO, HIROAKI) Jul 15, 2017 - Jun 30, 2020
    Novel oncolytic virotherapy for brain tumors
    Role: Principal Investigator
  3. R21NS067541 (WAKIMOTO, HIROAKI) Sep 25, 2009 - Aug 31, 2012
    Profiling and targeting micro-RNA expression during oncolytic virotherapy
    Role: Co-Principal Investigator

Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. Mohiuddin E, Wakimoto H. Extracellular matrix in glioblastoma: opportunities for emerging therapeutic approaches. Am J Cancer Res. 2021; 11(8):3742-3754. PMID: 34522446.
    Citations: 1     
  2. Aldrak N, Alsaab S, Algethami A, Bhere D, Wakimoto H, Shah K, Alomary MN, Zaidan N. Oncolytic Herpes Simplex Virus-Based Therapies for Cancer. Cells. 2021 06 18; 10(6). PMID: 34207386.
    Citations:    Fields:    
  3. Hara T, Chanoch-Myers R, Mathewson ND, Myskiw C, Atta L, Bussema L, Eichhorn SW, Greenwald AC, Kinker GS, Rodman C, Gonzalez Castro LN, Wakimoto H, Rozenblatt-Rosen O, Zhuang X, Fan J, Hunter T, Verma IM, Wucherpfennig KW, Regev A, Suvà ML, Tirosh I. Interactions between cancer cells and immune cells drive transitions to mesenchymal-like states in glioblastoma. Cancer Cell. 2021 Jun 14; 39(6):779-792.e11. PMID: 34087162.
    Citations: 10     Fields:    
  4. Bao Z, Hua L, Ye Y, Wang D, Li C, Xie Q, Wakimoto H, Ye G, Ji J. MEF2C silencing downregulates NF2 and E-cadherin and enhances Erastin-induced ferroptosis in meningioma. Neuro Oncol. 2021 May 13. PMID: 33984142.
    Citations:    Fields:    
  5. Xu L, Chen Y, Huang Y, Sandanaraj E, Yu JS, Lin RY, Dakle P, Ke XY, Chong YK, Koh L, Mayakonda A, Nacro K, Hill J, Huang ML, Gery S, Lim SW, Huang Z, Xu Y, Chen J, Bai L, Wang S, Wakimoto H, Yeo TT, Ang BT, Müschen M, Tang C, Tan TZ, Koeffler HP. Topography of transcriptionally active chromatin in glioblastoma. Sci Adv. 2021 Apr; 7(18). PMID: 33931443.
    Citations: 1     Fields:    
  6. Li M, Kirtane AR, Kiyokawa J, Nagashima H, Lopes A, Tirmizi ZA, Lee CK, Traverso G, Cahill DP, Wakimoto H. Local Targeting of NAD+ Salvage Pathway Alters the Immune Tumor Microenvironment and Enhances Checkpoint Immunotherapy in Glioblastoma. Cancer Res. 2021 Apr 01; 81(7):1922. PMID: 34003791.
    Citations:    Fields:    
  7. Song N, Wakimoto H, Rossignoli F, Bhere D, Ciccocioppo R, Chen KS, Khalsa JK, Mastrolia I, Samarelli AV, Dominici M, Shah K. Mesenchymal stem cell immunomodulation: In pursuit of controlling COVID-19 related cytokine storm. Stem Cells. 2021 06; 39(6):707-722. PMID: 33586320.
    Citations: 3     Fields:    Translation:HumansCellsPHPublic Health
  8. Galdieri L, Jash A, Malkova O, Mao DD, DeSouza P, Chu YE, Salter A, Campian JL, Naegle KM, Brennan CW, Wakimoto H, Oh ST, Kim AH, Chheda MG. Defining phenotypic and functional heterogeneity of glioblastoma stem cells by mass cytometry. JCI Insight. 2021 02 22; 6(4). PMID: 33400685.
    Citations: 1     Fields:    
  9. Mathewson ND, Ashenberg O, Tirosh I, Gritsch S, Perez EM, Marx S, Jerby-Arnon L, Chanoch-Myers R, Hara T, Richman AR, Ito Y, Pyrdol J, Friedrich M, Schumann K, Poitras MJ, Gokhale PC, Gonzalez Castro LN, Shore ME, Hebert CM, Shaw B, Cahill HL, Drummond M, Zhang W, Olawoyin O, Wakimoto H, Rozenblatt-Rosen O, Brastianos PK, Liu XS, Jones PS, Cahill DP, Frosch MP, Louis DN, Freeman GJ, Ligon KL, Marson A, Chiocca EA, Reardon DA, Regev A, Suvà ML, Wucherpfennig KW. Inhibitory CD161 receptor identified in glioma-infiltrating T cells by single-cell analysis. Cell. 2021 03 04; 184(5):1281-1298.e26. PMID: 33592174.
    Citations: 16     Fields:    Translation:AnimalsCells
  10. Miller JJ, Fink A, Banagis JA, Nagashima H, Subramanian M, Lee CK, Melamed L, Tummala SS, Tateishi K, Wakimoto H, Cahill DP. Sirtuin activation targets IDH-mutant tumors. Neuro Oncol. 2021 01 30; 23(1):53-62. PMID: 32710757.
    Citations: 4     Fields:    Translation:Humans
  11. Teng J, Hejazi S, Hiddingh L, Carvalho L, de Gooijer M, Wakimoto H, Barazas M, Tannous M, Chi AS, Noske DP, Wesseling P, Wurdinger T, Batchelor TT, Tannous BA. Corrigendum to: Recycling drug screen repurposes hydroxyurea as a sensitizer of glioblastomas to temozolomide targeting de novo DNA synthesis, irrespective of molecular subtype. Neuro Oncol. 2020 12 18; 22(12):1894. PMID: 33112953.
    Citations:    Fields:    
  12. Li M, Li G, Kiyokawa J, Tirmizi Z, Richardson LG, Ning J, Das S, Martuza RL, Stemmer-Rachamimov A, Rabkin SD, Wakimoto H. Characterization and oncolytic virus targeting of FAP-expressing tumor-associated pericytes in glioblastoma. Acta Neuropathol Commun. 2020 12 11; 8(1):221. PMID: 33308315.
    Citations: 4     Fields:    
  13. Kiyokawa J, Kawamura Y, Ghouse SM, Acar S, Barçin E, Martínez-Quintanilla J, Martuza RL, Alemany R, Rabkin SD, Shah K, Wakimoto H. Modification of Extracellular Matrix Enhances Oncolytic Adenovirus Immunotherapy in Glioblastoma. Clin Cancer Res. 2021 02 01; 27(3):889-902. PMID: 33257429.
    Citations: 6     Fields:    
  14. Wang D, Sun S, Hua L, Deng J, Luan S, Cheng H, Xie Q, Wakimoto H, Zhu H, Gong Y. Prognostic Model That Predicts Benefits of Adjuvant Radiotherapy in Patients With High Grade Meningioma. Front Oncol. 2020; 10:568079. PMID: 33240812.
    Citations: 1     
  15. Akter F, Simon B, de Boer NL, Redjal N, Wakimoto H, Shah K. Pre-clinical tumor models of primary brain tumors: Challenges and opportunities. Biochim Biophys Acta Rev Cancer. 2021 01; 1875(1):188458. PMID: 33148506.
    Citations: 2     Fields:    Translation:HumansAnimals
  16. Williams EA, Santagata S, Wakimoto H, Shankar GM, Barker FG, Sharaf R, Reddy A, Spear P, Alexander BM, Ross JS, Brastianos PK, Cahill DP, Ramkissoon SH, Juratli TA. Distinct genomic subclasses of high-grade/progressive meningiomas: NF2-associated, NF2-exclusive, and NF2-agnostic. Acta Neuropathol Commun. 2020 10 21; 8(1):171. PMID: 33087175.
    Citations: 3     Fields:    
  17. Tateishi K, Miyake Y, Kawazu M, Sasaki N, Nakamura T, Sasame J, Yoshii Y, Ueno T, Miyake A, Watanabe J, Matsushita Y, Shiba N, Udaka N, Ohki K, Fink AL, Tummala SS, Natsumeda M, Ikegaya N, Nishi M, Ohtake M, Miyazaki R, Suenaga J, Murata H, Aoki I, Miller JJ, Fujii Y, Ryo A, Yamanaka S, Mano H, Cahill DP, Wakimoto H, Chi AS, Batchelor TT, Nagane M, Ichimura K, Yamamoto T. A Hyperactive RelA/p65-Hexokinase 2 Signaling Axis Drives Primary Central Nervous System Lymphoma. Cancer Res. 2020 12 01; 80(23):5330-5343. PMID: 33067267.
    Citations: 5     Fields:    Translation:HumansAnimalsCells
  18. Li M, Kirtane AR, Kiyokawa J, Nagashima H, Lopes A, Tirmizi ZA, Lee CK, Traverso G, Cahill DP, Wakimoto H. Local Targeting of NAD+ Salvage Pathway Alters the Immune Tumor Microenvironment and Enhances Checkpoint Immunotherapy in Glioblastoma. Cancer Res. 2020 11 15; 80(22):5024-5034. PMID: 32998997.
    Citations: 2     Fields:    Translation:HumansAnimalsCells
  19. Hua L, Juratli TA, Zhu H, Deng J, Wang D, Sun S, Xie Q, Wakimoto H, Gong Y. High Tumor Mitochondrial DNA Content Correlates With an Improved Patient's Outcome in WHO Grade III Meningioma. Front Oncol. 2020; 10:542294. PMID: 33072573.
  20. Richardson LG, Nieman LT, Stemmer-Rachamimov AO, Zheng XS, Stafford K, Nagashima H, Miller JJ, Kiyokawa J, Ting DT, Wakimoto H, Cahill DP, Choi BD, Curry WT. IDH-mutant gliomas harbor fewer regulatory T cells in humans and mice. Oncoimmunology. 2020 08 20; 9(1):1806662. PMID: 32923170.
    Citations: 2     Translation:HumansAnimalsCells
  21. Nagashima H, Lee CK, Tateishi K, Higuchi F, Subramanian M, Rafferty S, Melamed L, Miller JJ, Wakimoto H, Cahill DP. Poly(ADP-ribose) Glycohydrolase Inhibition Sequesters NAD+ to Potentiate the Metabolic Lethality of Alkylating Chemotherapy in IDH-Mutant Tumor Cells. Cancer Discov. 2020 11; 10(11):1672-1689. PMID: 32606138.
    Citations: 7     Fields:    
  22. Chi AS, Cahill DP, Reardon DA, Wen PY, Mikkelsen T, Peereboom DM, Wong ET, Gerstner ER, Dietrich J, Plotkin SR, Norden AD, Lee EQ, Nayak L, Tanaka S, Wakimoto H, Lelic N, Koerner MV, Klofas LK, Bertalan MS, Arrillaga-Romany IC, Betensky RA, Curry WT, Borger DR, Balaj L, Kitchen RR, Chakrabortty SK, Valentino MD, Skog J, Breakefield XO, Iafrate AJ, Batchelor TT. Exploring Predictors of Response to Dacomitinib in EGFR-Amplified Recurrent Glioblastoma. JCO Precis Oncol. 2020; 4. PMID: 32923886.
    Citations: 3     
  23. Williams EA, Wakimoto H, Shankar GM, Barker FG, Brastianos PK, Santagata S, Sokol ES, Pavlick DC, Shah N, Reddy A, Venstrom JM, Alexander BM, Ross JS, Cahill DP, Ramkissoon SH, Juratli TA. Frequent inactivating mutations of the PBAF complex gene PBRM1 in meningioma with papillary features. Acta Neuropathol. 2020 07; 140(1):89-93. PMID: 32405805.
    Citations: 4     Fields:    Translation:Humans
  24. Hua L, Wang D, Zhu H, Deng J, Luan S, Chen H, Sun S, Tang H, Xie Q, Wakimoto H, Gong Y. Long-term outcomes of multimodality management for parasagittal meningiomas. J Neurooncol. 2020 Apr; 147(2):441-450. PMID: 32088814.
    Citations:    Fields:    Translation:Humans
  25. Ning J, Wakimoto H. Therapeutic Application of PARP Inhibitors in Neuro-Oncology. Trends Cancer. 2020 02; 6(2):147-159. PMID: 32061304.
    Citations: 3     Fields:    Translation:HumansAnimalsCells
  26. Higuchi F, Nagashima H, Ning J, Koerner MVA, Wakimoto H, Cahill DP. Restoration of Temozolomide Sensitivity by PARP Inhibitors in Mismatch Repair Deficient Glioblastoma is Independent of Base Excision Repair. Clin Cancer Res. 2020 04 01; 26(7):1690-1699. PMID: 31900275.
    Citations: 20     Fields:    Translation:HumansAnimalsCells
  27. Ito H, Watari K, Shibata T, Miyamoto T, Murakami Y, Nakahara Y, Izumi H, Wakimoto H, Kuwano M, Abe T, Ono M. Bidirectional Regulation between NDRG1 and GSK3ß Controls Tumor Growth and Is Targeted by Differentiation Inducing Factor-1 in Glioblastoma. Cancer Res. 2020 01 15; 80(2):234-248. PMID: 31723002.
    Citations: 3     Fields:    Translation:HumansCells
  28. Ippen FM, Grosch JK, Subramanian M, Kuter BM, Liederer BM, Plise EG, Mora JL, Nayyar N, Schmidt SP, Giobbie-Hurder A, Martinez-Lage M, Carter SL, Cahill DP, Wakimoto H, Brastianos PK. Targeting the PI3K/Akt/mTOR pathway with the pan-Akt inhibitor GDC-0068 in PIK3CA-mutant breast cancer brain metastases. Neuro Oncol. 2019 11 04; 21(11):1401-1411. PMID: 31173106.
    Citations: 16     Fields:    Translation:HumansAnimalsCells
  29. Seker F, Cingoz A, Sur-Erdem I, Erguder N, Erkent A, Uyulur F, Esai Selvan M, Gümüs ZH, Gönen M, Bayraktar H, Wakimoto H, Bagci-Onder T. Identification of SERPINE1 as a Regulator of Glioblastoma Cell Dispersal with Transcriptome Profiling. Cancers (Basel). 2019 Oct 25; 11(11). PMID: 31731490.
    Citations: 7     
  30. Kiyokawa J, Wakimoto H. Preclinical And Clinical Development Of Oncolytic Adenovirus For The Treatment Of Malignant Glioma. Oncolytic Virother. 2019; 8:27-37. PMID: 31750274.
    Citations: 16     
  31. Nigim F, Kiyokawa J, Gurtner A, Kawamura Y, Hua L, Kasper EM, Brastianos PK, Cahill DP, Rabkin SD, Martuza RL, Carbonell WS, Wakimoto H. A Monoclonal Antibody Against ß1 Integrin Inhibits Proliferation and Increases Survival in an Orthotopic Model of High-Grade Meningioma. Target Oncol. 2019 08; 14(4):479-489. PMID: 31301014.
    Citations: 3     Fields:    Translation:HumansAnimals
  32. Kofuji S, Hirayama A, Eberhardt AO, Kawaguchi R, Sugiura Y, Sampetrean O, Ikeda Y, Warren M, Sakamoto N, Kitahara S, Yoshino H, Yamashita D, Sumita K, Wolfe K, Lange L, Ikeda S, Shimada H, Minami N, Malhotra A, Morioka S, Ban Y, Asano M, Flanary VL, Ramkissoon A, Chow LML, Kiyokawa J, Mashimo T, Lucey G, Mareninov S, Ozawa T, Onishi N, Okumura K, Terakawa J, Daikoku T, Wise-Draper T, Majd N, Kofuji K, Sasaki M, Mori M, Kanemura Y, Smith EP, Anastasiou D, Wakimoto H, Holland EC, Yong WH, Horbinski C, Nakano I, DeBerardinis RJ, Bachoo RM, Mischel PS, Yasui W, Suematsu M, Saya H, Soga T, Grummt I, Bierhoff H, Sasaki AT. IMP dehydrogenase-2 drives aberrant nucleolar activity and promotes tumorigenesis in glioblastoma. Nat Cell Biol. 2019 08; 21(8):1003-1014. PMID: 31371825.
    Citations: 25     Fields:    Translation:HumansCells
  33. Tabatabai G, Wakimoto H. Glioblastoma: State of the Art and Future Perspectives. Cancers (Basel). 2019 Jul 31; 11(8). PMID: 31370300.
    Citations: 1     
  34. Choi BD, Yu X, Castano AP, Bouffard AA, Schmidts A, Larson RC, Bailey SR, Boroughs AC, Frigault MJ, Leick MB, Scarfò I, Cetrulo CL, Demehri S, Nahed BV, Cahill DP, Wakimoto H, Curry WT, Carter BS, Maus MV. CAR-T cells secreting BiTEs circumvent antigen escape without detectable toxicity. Nat Biotechnol. 2019 09; 37(9):1049-1058. PMID: 31332324.
    Citations: 88     Fields:    Translation:HumansAnimalsCells
  35. Neftel C, Laffy J, Filbin MG, Hara T, Shore ME, Rahme GJ, Richman AR, Silverbush D, Shaw ML, Hebert CM, Dewitt J, Gritsch S, Perez EM, Gonzalez Castro LN, Lan X, Druck N, Rodman C, Dionne D, Kaplan A, Bertalan MS, Small J, Pelton K, Becker S, Bonal D, Nguyen QD, Servis RL, Fung JM, Mylvaganam R, Mayr L, Gojo J, Haberler C, Geyeregger R, Czech T, Slavc I, Nahed BV, Curry WT, Carter BS, Wakimoto H, Brastianos PK, Batchelor TT, Stemmer-Rachamimov A, Martinez-Lage M, Frosch MP, Stamenkovic I, Riggi N, Rheinbay E, Monje M, Rozenblatt-Rosen O, Cahill DP, Patel AP, Hunter T, Verma IM, Ligon KL, Louis DN, Regev A, Bernstein BE, Tirosh I, Suvà ML. An Integrative Model of Cellular States, Plasticity, and Genetics for Glioblastoma. Cell. 2019 08 08; 178(4):835-849.e21. PMID: 31327527.
    Citations: 266     Fields:    Translation:HumansAnimalsCells
  36. Ning JF, Stanciu M, Humphrey MR, Gorham J, Wakimoto H, Nishihara R, Lees J, Zou L, Martuza RL, Wakimoto H, Rabkin SD. Myc targeted CDK18 promotes ATR and homologous recombination to mediate PARP inhibitor resistance in glioblastoma. Nat Commun. 2019 07 02; 10(1):2910. PMID: 31266951.
    Citations: 21     Fields:    Translation:HumansAnimalsCells
  37. Hua L, Wakimoto H. Oncolytic herpes simplex virus therapy for malignant glioma: current approaches to successful clinical application. Expert Opin Biol Ther. 2019 08; 19(8):845-854. PMID: 31046478.
    Citations: 7     Fields:    Translation:HumansAnimalsCells
  38. Tateishi K, Nakamura T, Juratli TA, Williams EA, Matsushita Y, Miyake S, Nishi M, Miller JJ, Tummala SS, Fink AL, Lelic N, Koerner MVA, Miyake Y, Sasame J, Fujimoto K, Tanaka T, Minamimoto R, Matsunaga S, Mukaihara S, Shuto T, Taguchi H, Udaka N, Murata H, Ryo A, Yamanaka S, Curry WT, Dias-Santagata D, Yamamoto T, Ichimura K, Batchelor TT, Chi AS, Iafrate AJ, Wakimoto H, Cahill DP. PI3K/AKT/mTOR Pathway Alterations Promote Malignant Progression and Xenograft Formation in Oligodendroglial Tumors. Clin Cancer Res. 2019 07 15; 25(14):4375-4387. PMID: 30975663.
    Citations: 8     Fields:    Translation:HumansAnimalsCells
  39. Wakimoto H. Deubiquitinating ALDH1A3 key to maintaining the culprit of aggressive brain cancer. J Clin Invest. 2019 04 08; 129(5):1833-1835. PMID: 30958802.
    Citations:    Fields:    Translation:HumansCells
  40. Wang L, Ning J, Wakimoto H, Wu S, Wu CL, Humphrey MR, Rabkin SD, Martuza RL. Oncolytic Herpes Simplex Virus and PI3K Inhibitor BKM120 Synergize to Promote Killing of Prostate Cancer Stem-like Cells. Mol Ther Oncolytics. 2019 Jun 28; 13:58-66. PMID: 31016228.
    Citations: 5     
  41. Ippen FM, Alvarez-Breckenridge CA, Kuter BM, Fink AL, Bihun IV, Lastrapes M, Penson T, Schmidt SP, Wojtkiewicz GR, Ning J, Subramanian M, Giobbie-Hurder A, Martinez-Lage M, Carter SL, Cahill DP, Wakimoto H, Brastianos PK. The Dual PI3K/mTOR Pathway Inhibitor GDC-0084 Achieves Antitumor Activity in PIK3CA-Mutant Breast Cancer Brain Metastases. Clin Cancer Res. 2019 06 01; 25(11):3374-3383. PMID: 30796030.
    Citations: 14     Fields:    Translation:HumansAnimalsCells
  42. Tanaka S, Luk S, Kiyokawa J, Onozato ML, Iafrate AJ, Shah K, Martuza RL, Rabkin SD, Batchelor TT, Cahill DP, Chi AS, Wakimoto H. Genetically distinct glioma stem-like cell xenografts established from paired glioblastoma samples harvested before and after molecularly targeted therapy. Sci Rep. 2019 01 15; 9(1):139. PMID: 30644426.
    Citations: 2     Fields:    Translation:HumansAnimalsCells
  43. Kahramanian A, Kuroda T, Wakimoto H. Construction of Oncolytic Herpes Simplex Virus with Therapeutic Genes of Interest. Methods Mol Biol. 2019; 1937:177-188. PMID: 30706396.
    Citations: 2     Fields:    Translation:HumansAnimalsCells
  44. Spino M, Kurz SC, Chiriboga L, Serrano J, Zeck B, Sen N, Patel S, Shen G, Vasudevaraja V, Tsirigos A, Suryadevara CM, Frenster JD, Tateishi K, Wakimoto H, Jain R, Riina HA, Nicolaides TP, Sulman EP, Cahill DP, Golfinos JG, Isse K, Saunders LR, Zagzag D, Placantonakis DG, Snuderl M, Chi AS. Cell Surface Notch Ligand DLL3 is a Therapeutic Target in Isocitrate Dehydrogenase-mutant Glioma. Clin Cancer Res. 2019 02 15; 25(4):1261-1271. PMID: 30397180.
    Citations: 15     Fields:    Translation:HumansCells
  45. Higuchi F, Fink AL, Kiyokawa J, Miller JJ, Koerner MVA, Cahill DP, Wakimoto H. PLK1 Inhibition Targets Myc-Activated Malignant Glioma Cells Irrespective of Mismatch Repair Deficiency-Mediated Acquired Resistance to Temozolomide. . 2018 12; 17(12):2551-2563. PMID: 30217967.
    Citations: 9     Translation:HumansAnimalsCells
  46. Hua L, Zhu H, Deng J, Tian M, Jiang X, Tang H, Luan S, Wakimoto H, Xie Q, Gong Y. Clinical and prognostic features of spinal meningioma: a thorough analysis from a single neurosurgical center. J Neurooncol. 2018 Dec; 140(3):639-647. PMID: 30209689.
    Citations: 7     Fields:    Translation:Humans
  47. Juratli TA, McCabe D, Nayyar N, Williams EA, Silverman IM, Tummala SS, Fink AL, Baig A, Martinez-Lage M, Selig MK, Bihun IV, Shankar GM, Penson T, Lastrapes M, Daubner D, Meinhardt M, Hennig S, Kaplan AB, Fujio S, Kuter BM, Bertalan MS, Miller JJ, Batten JM, Ely HA, Christiansen J, Baretton GB, Stemmer-Rachamimov AO, Santagata S, Rivera MN, Barker FG, Schackert G, Wakimoto H, Iafrate AJ, Carter SL, Cahill DP, Brastianos PK. DMD genomic deletions characterize a subset of progressive/higher-grade meningiomas with poor outcome. Acta Neuropathol. 2018 11; 136(5):779-792. PMID: 30123936.
    Citations: 16     Fields:    Translation:HumansCells
  48. Nigim F, Wakimoto H, Kasper EM, Ackermans L, Temel Y. Emerging Medical Treatments for Meningioma in the Molecular Era. Biomedicines. 2018 Aug 06; 6(3). PMID: 30082628.
    Citations: 9     
  49. Shankar GM, Kirtane AR, Miller JJ, Mazdiyasni H, Rogner J, Tai T, Williams EA, Higuchi F, Juratli TA, Tateishi K, Koerner MVA, Tummala SS, Fink AL, Penson T, Schmidt SP, Wojtkiewicz GR, Baig A, Francis JM, Rinne ML, Batten JM, Batchelor TT, Brastianos PK, Curry WT, Barker FG, Jordan JT, Iafrate AJ, Chi AS, Lennerz JK, Meyerson M, Langer R, Wakimoto H, Traverso G, Cahill DP. Genotype-targeted local therapy of glioma. Proc Natl Acad Sci U S A. 2018 09 04; 115(36):E8388-E8394. PMID: 30082399.
    Citations: 16     Fields:    Translation:HumansAnimals
  50. Peters C, Paget M, Tshilenge KT, Saha D, Antoszczyk S, Baars A, Frost T, Martuza RL, Wakimoto H, Rabkin SD. Restriction of Replication of Oncolytic Herpes Simplex Virus with a Deletion of ?34.5 in Glioblastoma Stem-Like Cells. J Virol. 2018 08 01; 92(15). PMID: 29793956.
    Citations: 13     Fields:    Translation:AnimalsCells
  51. Reinshagen C, Bhere D, Choi SH, Hutten S, Nesterenko I, Wakimoto H, Le Roux E, Rizvi A, Du W, Minicucci C, Shah K. CRISPR-enhanced engineering of therapy-sensitive cancer cells for self-targeting of primary and metastatic tumors. Sci Transl Med. 2018 07 11; 10(449). PMID: 29997250.
    Citations: 7     Fields:    Translation:HumansAnimalsCells
  52. Teng J, Hejazi S, Hiddingh L, Carvalho L, de Gooijer MC, Wakimoto H, Barazas M, Tannous M, Chi AS, Noske DP, Wesseling P, Wurdinger T, Batchelor TT, Tannous BA. Recycling drug screen repurposes hydroxyurea as a sensitizer of glioblastomas to temozolomide targeting de novo DNA synthesis, irrespective of molecular subtype. Neuro Oncol. 2018 04 09; 20(5):642-654. PMID: 29099956.
    Citations: 13     Fields:    Translation:HumansAnimalsCells
  53. Saha D, Wakimoto H, Peters CW, Antoszczyk SJ, Rabkin SD, Martuza RL. Combinatorial Effects of VEGFR Kinase Inhibitor Axitinib and Oncolytic Virotherapy in Mouse and Human Glioblastoma Stem-Like Cell Models. Clin Cancer Res. 2018 07 15; 24(14):3409-3422. PMID: 29599413.
    Citations: 13     Fields:    Translation:HumansAnimalsCells
  54. Bhere D, Tamura K, Wakimoto H, Choi SH, Purow B, Debatisse J, Shah K. microRNA-7 upregulates death receptor 5 and primes resistant brain tumors to caspase-mediated apoptosis. Neuro Oncol. 2018 01 22; 20(2):215-224. PMID: 29016934.
    Citations: 12     Fields:    Translation:HumansAnimalsCells
  55. Juratli TA, Thiede C, Koerner MVA, Tummala SS, Daubner D, Shankar GM, Williams EA, Martinez-Lage M, Soucek S, Robel K, Penson T, Krause M, Appold S, Meinhardt M, Pinzer T, Miller JJ, Krex D, Ely HA, Silverman IM, Christiansen J, Schackert G, Wakimoto H, Kirsch M, Brastianos PK, Cahill DP. Intratumoral heterogeneity and TERT promoter mutations in progressive/higher-grade meningiomas. Oncotarget. 2017 Dec 12; 8(65):109228-109237. PMID: 29312603.
    Citations: 22     Fields:    
  56. Braun CJ, Stanciu M, Boutz PL, Patterson JC, Calligaris D, Higuchi F, Neupane R, Fenoglio S, Cahill DP, Wakimoto H, Agar NYR, Yaffe MB, Sharp PA, Hemann MT, Lees JA. Coordinated Splicing of Regulatory Detained Introns within Oncogenic Transcripts Creates an Exploitable Vulnerability in Malignant Glioma. Cancer Cell. 2017 10 09; 32(4):411-426.e11. PMID: 28966034.
    Citations: 58     Fields:    Translation:HumansAnimalsCells
  57. Tateishi K, Wakimoto H, Cahill DP. IDH1 Mutation and World Health Organization 2016 Diagnostic Criteria for Adult Diffuse Gliomas: Advances in Surgical Strategy. Neurosurgery. 2017 09 01; 64(CN_suppl_1):134-138. PMID: 28899049.
    Citations: 10     Fields:    
  58. Esaki S, Nigim F, Moon E, Luk S, Kiyokawa J, Curry W, Cahill DP, Chi AS, Iafrate AJ, Martuza RL, Rabkin SD, Wakimoto H. Blockade of transforming growth factor-ß signaling enhances oncolytic herpes simplex virus efficacy in patient-derived recurrent glioblastoma models. Int J Cancer. 2017 12 01; 141(11):2348-2358. PMID: 28801914.
    Citations: 12     Fields:    Translation:HumansAnimalsCells
  59. Jahan N, Lee JM, Shah K, Wakimoto H. Therapeutic targeting of chemoresistant and recurrent glioblastoma stem cells with a proapoptotic variant of oncolytic herpes simplex virus. Int J Cancer. 2017 10 15; 141(8):1671-1681. PMID: 28567859.
    Citations: 10     Fields:    Translation:HumansAnimalsCells
  60. Du W, Seah I, Bougazzoul O, Choi G, Meeth K, Bosenberg MW, Wakimoto H, Fisher D, Shah K. Stem cell-released oncolytic herpes simplex virus has therapeutic efficacy in brain metastatic melanomas. Proc Natl Acad Sci U S A. 2017 07 25; 114(30):E6157-E6165. PMID: 28710334.
    Citations: 31     Fields:    Translation:HumansAnimalsCells
  61. Tateishi K, Higuchi F, Miller JJ, Koerner MVA, Lelic N, Shankar GM, Tanaka S, Fisher DE, Batchelor TT, Iafrate AJ, Wakimoto H, Chi AS, Cahill DP. The Alkylating Chemotherapeutic Temozolomide Induces Metabolic Stress in IDH1-Mutant Cancers and Potentiates NAD+ Depletion-Mediated Cytotoxicity. Cancer Res. 2017 08 01; 77(15):4102-4115. PMID: 28625978.
    Citations: 32     Fields:    Translation:HumansAnimalsCells
  62. Teng J, da Hora CC, Kantar RS, Nakano I, Wakimoto H, Batchelor TT, Chiocca EA, Badr CE, Tannous BA. Dissecting inherent intratumor heterogeneity in patient-derived glioblastoma culture models. Neuro Oncol. 2017 06 01; 19(6):820-832. PMID: 28062830.
    Citations: 26     Fields:    Translation:HumansAnimalsCells
  63. Venteicher AS, Tirosh I, Hebert C, Yizhak K, Neftel C, Filbin MG, Hovestadt V, Escalante LE, Shaw ML, Rodman C, Gillespie SM, Dionne D, Luo CC, Ravichandran H, Mylvaganam R, Mount C, Onozato ML, Nahed BV, Wakimoto H, Curry WT, Iafrate AJ, Rivera MN, Frosch MP, Golub TR, Brastianos PK, Getz G, Patel AP, Monje M, Cahill DP, Rozenblatt-Rosen O, Louis DN, Bernstein BE, Regev A, Suvà ML. Decoupling genetics, lineages, and microenvironment in IDH-mutant gliomas by single-cell RNA-seq. Science. 2017 03 31; 355(6332). PMID: 28360267.
    Citations: 225     Fields:    Translation:HumansCells
  64. Ning J, Wakimoto H, Peters C, Martuza RL, Rabkin SD. Rad51 Degradation: Role in Oncolytic Virus-Poly(ADP-Ribose) Polymerase Inhibitor Combination Therapy in Glioblastoma. J Natl Cancer Inst. 2017 03 01; 109(3):1-13. PMID: 28376211.
    Citations: 16     Fields:    Translation:HumansAnimalsCells
  65. Liau BB, Sievers C, Donohue LK, Gillespie SM, Flavahan WA, Miller TE, Venteicher AS, Hebert CH, Carey CD, Rodig SJ, Shareef SJ, Najm FJ, van Galen P, Wakimoto H, Cahill DP, Rich JN, Aster JC, Suvà ML, Patel AP, Bernstein BE. Adaptive Chromatin Remodeling Drives Glioblastoma Stem Cell Plasticity and Drug Tolerance. Cell Stem Cell. 2017 02 02; 20(2):233-246.e7. PMID: 27989769.
    Citations: 126     Fields:    Translation:HumansCells
  66. Wong HA, Fatimy RE, Onodera C, Wei Z, Yi M, Mohan A, Gowrisankaran S, Karmali P, Marcusson E, Wakimoto H, Stephens R, Uhlmann EJ, Song JS, Tannous B, Krichevsky AM. The Cancer Genome Atlas Analysis Predicts MicroRNA for Targeting Cancer Growth and Vascularization in Glioblastoma. Mol Ther. 2015 Jul; 23(7):1234-1247. PMID: 28142001.
  67. Saha D, Wakimoto H, Rabkin SD. Oncolytic herpes simplex virus interactions with the host immune system. Curr Opin Virol. 2016 12; 21:26-34. PMID: 27497296.
    Citations: 20     Fields:    Translation:HumansAnimalsCells
  68. Tateishi K, Iafrate AJ, Ho Q, Curry WT, Batchelor TT, Flaherty KT, Onozato ML, Lelic N, Sundaram S, Cahill DP, Chi AS, Wakimoto H. Myc-Driven Glycolysis Is a Therapeutic Target in Glioblastoma. Clin Cancer Res. 2016 Sep 01; 22(17):4452-65. PMID: 27076630.
    Citations: 47     Fields:    Translation:HumansAnimalsCells
  69. Kloepper J, Riedemann L, Amoozgar Z, Seano G, Susek K, Yu V, Dalvie N, Amelung RL, Datta M, Song JW, Askoxylakis V, Taylor JW, Lu-Emerson C, Batista A, Kirkpatrick ND, Jung K, Snuderl M, Muzikansky A, Stubenrauch KG, Krieter O, Wakimoto H, Xu L, Munn LL, Duda DG, Fukumura D, Batchelor TT, Jain RK. Ang-2/VEGF bispecific antibody reprograms macrophages and resident microglia to anti-tumor phenotype and prolongs glioblastoma survival. Proc Natl Acad Sci U S A. 2016 Apr 19; 113(16):4476-81. PMID: 27044098.
    Citations: 101     Fields:    Translation:HumansAnimalsCells
  70. Tsuchihashi K, Okazaki S, Ohmura M, Ishikawa M, Sampetrean O, Onishi N, Wakimoto H, Yoshikawa M, Seishima R, Iwasaki Y, Morikawa T, Abe S, Takao A, Shimizu M, Masuko T, Nagane M, Furnari FB, Akiyama T, Suematsu M, Baba E, Akashi K, Saya H, Nagano O. The EGF Receptor Promotes the Malignant Potential of Glioma by Regulating Amino Acid Transport System xc(-). Cancer Res. 2016 05 15; 76(10):2954-63. PMID: 26980765.
    Citations: 34     Fields:    Translation:HumansAnimalsCells
  71. Nigim F, Esaki S, Hood M, Lelic N, James MF, Ramesh V, Stemmer-Rachamimov A, Cahill DP, Brastianos PK, Rabkin SD, Martuza RL, Wakimoto H. A new patient-derived orthotopic malignant meningioma model treated with oncolytic herpes simplex virus. Neuro Oncol. 2016 09; 18(9):1278-87. PMID: 26951380.
    Citations: 8     Fields:    Translation:HumansAnimalsCells
  72. Gerweck LE, Wakimoto H. At the Crossroads of Cancer Stem Cells, Radiation Biology, and Radiation Oncology. Cancer Res. 2016 Mar 01; 76(5):994-8. PMID: 26880806.
    Citations: 13     Fields:    Translation:HumansCells
  73. Esaki S, Rabkin SD, Martuza RL, Wakimoto H. Transient fasting enhances replication of oncolytic herpes simplex virus in glioblastoma. Am J Cancer Res. 2016; 6(2):300-11. PMID: 27186404.
    Citations: 7     
  74. Tateishi K, Wakimoto H, Iafrate AJ, Tanaka S, Loebel F, Lelic N, Wiederschain D, Bedel O, Deng G, Zhang B, He T, Shi X, Gerszten RE, Zhang Y, Yeh JJ, Curry WT, Zhao D, Sundaram S, Nigim F, Koerner MVA, Ho Q, Fisher DE, Roider EM, Kemeny LV, Samuels Y, Flaherty KT, Batchelor TT, Chi AS, Cahill DP. Extreme Vulnerability of IDH1 Mutant Cancers to NAD+ Depletion. Cancer Cell. 2015 Dec 14; 28(6):773-784. PMID: 26678339.
    Citations: 140     Fields:    Translation:HumansAnimalsCells
  75. Nigim F, Cavanaugh J, Patel AP, Curry WT, Esaki S, Kasper EM, Chi AS, Louis DN, Martuza RL, Rabkin SD, Wakimoto H. Targeting Hypoxia-Inducible Factor 1a in a New Orthotopic Model of Glioblastoma Recapitulating the Hypoxic Tumor Microenvironment. J Neuropathol Exp Neurol. 2015 Jul; 74(7):710-22. PMID: 26083570.
    Citations: 14     Fields:    Translation:HumansAnimalsCells
  76. Wong HA, Fatimy RE, Onodera C, Wei Z, Yi M, Mohan A, Gowrisankaran S, Karmali P, Marcusson E, Wakimoto H, Stephens R, Uhlmann EJ, Song JS, Tannous B, Krichevsky AM. The Cancer Genome Atlas Analysis Predicts MicroRNA for Targeting Cancer Growth and Vascularization in Glioblastoma. Mol Ther. 2015 Jul; 23(7):1234-1247. PMID: 25903473.
    Citations: 28     Fields:    Translation:HumansAnimalsCells
  77. Flynn RL, Cox KE, Jeitany M, Wakimoto H, Bryll AR, Ganem NJ, Bersani F, Pineda JR, Suvà ML, Benes CH, Haber DA, Boussin FD, Zou L. Alternative lengthening of telomeres renders cancer cells hypersensitive to ATR inhibitors. Science. 2015 Jan 16; 347(6219):273-7. PMID: 25593184.
    Citations: 158     Fields:    Translation:HumansCells
  78. Martinez-Quintanilla J, He D, Wakimoto H, Alemany R, Shah K. Encapsulated stem cells loaded with hyaluronidase-expressing oncolytic virus for brain tumor therapy. Mol Ther. 2015 Jan; 23(1):108-18. PMID: 25352242.
    Citations: 35     Fields:    Translation:HumansAnimalsCells
  79. Lu L, Saha D, Martuza RL, Rabkin SD, Wakimoto H. Single agent efficacy of the VEGFR kinase inhibitor axitinib in preclinical models of glioblastoma. J Neurooncol. 2015 Jan; 121(1):91-100. PMID: 25213669.
    Citations: 14     Fields:    Translation:HumansAnimalsCells
  80. Sullivan JP, Nahed BV, Madden MW, Oliveira SM, Springer S, Bhere D, Chi AS, Wakimoto H, Rothenberg SM, Sequist LV, Kapur R, Shah K, Iafrate AJ, Curry WT, Loeffler JS, Batchelor TT, Louis DN, Toner M, Maheswaran S, Haber DA. Brain tumor cells in circulation are enriched for mesenchymal gene expression. Cancer Discov. 2014 Nov; 4(11):1299-309. PMID: 25139148.
    Citations: 91     Fields:    Translation:HumansAnimalsCells
  81. Balvers RK, Belcaid Z, van den Hengel SK, Kloezeman J, de Vrij J, Wakimoto H, Hoeben RC, Debets R, Leenstra S, Dirven C, Lamfers ML. Locally-delivered T-cell-derived cellular vehicles efficiently track and deliver adenovirus delta24-RGD to infiltrating glioma. Viruses. 2014 Aug 12; 6(8):3080-96. PMID: 25118638.
    Citations: 7     Fields:    Translation:HumansAnimalsCells
  82. Nahed BV, Sullivan JP, Madden MW, Oliveira SM, Chi AS, Springer S, Wakimoto H, Bhere D, Shah A, Spuhler P, Batchelor T, Louis DN, Toner M, Maheswaran S, Haber DA. American brain tumor association young investigator award 198 circulating tumor cells in patients with glioblastoma. Neurosurgery. 2014 Aug; 61 Suppl 1:226. PMID: 25032649.
  83. Ning J, Wakimoto H. Oncolytic herpes simplex virus-based strategies: toward a breakthrough in glioblastoma therapy. Front Microbiol. 2014; 5:303. PMID: 24999342.
    Citations: 22     
  84. Patel AP, Tirosh I, Trombetta JJ, Shalek AK, Gillespie SM, Wakimoto H, Cahill DP, Nahed BV, Curry WT, Martuza RL, Louis DN, Rozenblatt-Rosen O, Suvà ML, Regev A, Bernstein BE. Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma. Science. 2014 Jun 20; 344(6190):1396-401. PMID: 24925914.
    Citations: 1321     Fields:    Translation:Humans
  85. Duebgen M, Martinez-Quintanilla J, Tamura K, Hingtgen S, Redjal N, Wakimoto H, Shah K. Stem cells loaded with multimechanistic oncolytic herpes simplex virus variants for brain tumor therapy. J Natl Cancer Inst. 2014 Jun; 106(6):dju090. PMID: 24838834.
    Citations: 43     Fields:    Translation:HumansAnimalsCells
  86. Suvà ML, Rheinbay E, Gillespie SM, Patel AP, Wakimoto H, Rabkin SD, Riggi N, Chi AS, Cahill DP, Nahed BV, Curry WT, Martuza RL, Rivera MN, Rossetti N, Kasif S, Beik S, Kadri S, Tirosh I, Wortman I, Shalek AK, Rozenblatt-Rosen O, Regev A, Louis DN, Bernstein BE. Reconstructing and reprogramming the tumor-propagating potential of glioblastoma stem-like cells. Cell. 2014 Apr 24; 157(3):580-94. PMID: 24726434.
    Citations: 333     Fields:    Translation:HumansCells
  87. Wakimoto H, Tanaka S, Curry WT, Loebel F, Zhao D, Tateishi K, Chen J, Klofas LK, Lelic N, Kim JC, Dias-Santagata D, Ellisen LW, Borger DR, Fendt SM, Vander Heiden MG, Batchelor TT, Iafrate AJ, Cahill DP, Chi AS. Targetable signaling pathway mutations are associated with malignant phenotype in IDH-mutant gliomas. Clin Cancer Res. 2014 Jun 01; 20(11):2898-909. PMID: 24714777.
    Citations: 63     Fields:    Translation:HumansAnimals
  88. Ning J, Wakimoto H, Rabkin SD. Immunovirotherapy for glioblastoma. Cell Cycle. 2014; 13(2):175-6. PMID: 24241205.
    Citations: 6     Fields:    Translation:AnimalsCells
  89. Tamura K, Aoyagi M, Ando N, Ogishima T, Wakimoto H, Yamamoto M, Ohno K. Expansion of CD133-positive glioma cells in recurrent de novo glioblastomas after radiotherapy and chemotherapy. J Neurosurg. 2013 Nov; 119(5):1145-55. PMID: 23991844.
    Citations: 30     Fields:    Translation:HumansCellsPHPublic Health
  90. Cheema TA, Wakimoto H, Fecci PE, Ning J, Kuroda T, Jeyaretna DS, Martuza RL, Rabkin SD. Multifaceted oncolytic virus therapy for glioblastoma in an immunocompetent cancer stem cell model. Proc Natl Acad Sci U S A. 2013 Jul 16; 110(29):12006-11. PMID: 23754388.
    Citations: 84     Fields:    Translation:AnimalsCells
  91. Zhang W, Fulci G, Wakimoto H, Cheema TA, Buhrman JS, Jeyaretna DS, Stemmer Rachamimov AO, Rabkin SD, Martuza RL. Combination of oncolytic herpes simplex viruses armed with angiostatin and IL-12 enhances antitumor efficacy in human glioblastoma models. Neoplasia. 2013 Jun; 15(6):591-9. PMID: 23730207.
    Citations: 30     Fields:    Translation:HumansAnimalsCells
  92. Rheinbay E, Suvà ML, Gillespie SM, Wakimoto H, Patel AP, Shahid M, Oksuz O, Rabkin SD, Martuza RL, Rivera MN, Louis DN, Kasif S, Chi AS, Bernstein BE. An aberrant transcription factor network essential for Wnt signaling and stem cell maintenance in glioblastoma. Cell Rep. 2013 May 30; 3(5):1567-79. PMID: 23707066.
    Citations: 106     Fields:    Translation:HumansCells
  93. van de Water JA, Bagci-Onder T, Agarwal AS, Wakimoto H, Roovers RC, Zhu Y, Kasmieh R, Bhere D, Van Bergen en Henegouwen PM, Shah K. Therapeutic stem cells expressing variants of EGFR-specific nanobodies have antitumor effects. Proc Natl Acad Sci U S A. 2012 Oct 09; 109(41):16642-7. PMID: 23012408.
    Citations: 29     Fields:    Translation:HumansAnimalsCells
  94. Barnard Z, Wakimoto H, Zaupa C, Patel AP, Klehm J, Martuza RL, Rabkin SD, Curry WT. Expression of FMS-like tyrosine kinase 3 ligand by oncolytic herpes simplex virus type I prolongs survival in mice bearing established syngeneic intracranial malignant glioma. Neurosurgery. 2012 Sep; 71(3):741-8; discussion 748. PMID: 22653387.
    Citations: 12     Fields:    Translation:AnimalsCells
  95. Tamura K, Wakimoto H, Agarwal AS, Rabkin SD, Bhere D, Martuza RL, Kuroda T, Kasmieh R, Shah K. Multimechanistic tumor targeted oncolytic virus overcomes resistance in brain tumors. Mol Ther. 2013 Jan; 21(1):68-77. PMID: 22929661.
    Citations: 22     Fields:    Translation:HumansAnimalsCells
  96. Lee C, Fotovati A, Triscott J, Chen J, Venugopal C, Singhal A, Dunham C, Kerr JM, Verreault M, Yip S, Wakimoto H, Jones C, Jayanthan A, Narendran A, Singh SK, Dunn SE. Polo-like kinase 1 inhibition kills glioblastoma multiforme brain tumor cells in part through loss of SOX2 and delays tumor progression in mice. Stem Cells. 2012 Jun; 30(6):1064-75. PMID: 22415968.
    Citations: 34     Fields:    Translation:HumansAnimalsCells
  97. Sgubin D, Wakimoto H, Kanai R, Rabkin SD, Martuza RL. Oncolytic herpes simplex virus counteracts the hypoxia-induced modulation of glioblastoma stem-like cells. Stem Cells Transl Med. 2012 Apr; 1(4):322-32. PMID: 23197811.
    Citations: 17     Fields:    Translation:HumansAnimalsCells
  98. Kanai R, Zaupa C, Sgubin D, Antoszczyk SJ, Martuza RL, Wakimoto H, Rabkin SD. Effect of ?34.5 deletions on oncolytic herpes simplex virus activity in brain tumors. J Virol. 2012 Apr; 86(8):4420-31. PMID: 22345479.
    Citations: 47     Fields:    Translation:HumansAnimalsCells
  99. Kanai R, Rabkin SD, Yip S, Sgubin D, Zaupa CM, Hirose Y, Louis DN, Wakimoto H, Martuza RL. Oncolytic virus-mediated manipulation of DNA damage responses: synergy with chemotherapy in killing glioblastoma stem cells. J Natl Cancer Inst. 2012 Jan 04; 104(1):42-55. PMID: 22173583.
    Citations: 53     Fields:    Translation:HumansAnimalsCells
  100. Wakimoto H, Mohapatra G, Kanai R, Curry WT, Yip S, Nitta M, Patel AP, Barnard ZR, Stemmer-Rachamimov AO, Louis DN, Martuza RL, Rabkin SD. Maintenance of primary tumor phenotype and genotype in glioblastoma stem cells. Neuro Oncol. 2012 Feb; 14(2):132-44. PMID: 22067563.
    Citations: 126     Fields:    Translation:HumansAnimalsCells
  101. Cheema TA, Kanai R, Kim GW, Wakimoto H, Passer B, Rabkin SD, Martuza RL. Enhanced antitumor efficacy of low-dose Etoposide with oncolytic herpes simplex virus in human glioblastoma stem cell xenografts. Clin Cancer Res. 2011 Dec 01; 17(23):7383-93. PMID: 21976549.
    Citations: 38     Fields:    Translation:HumansAnimalsCells
  102. Fotovati A, Abu-Ali S, Wang PS, Deleyrolle LP, Lee C, Triscott J, Chen JY, Franciosi S, Nakamura Y, Sugita Y, Uchiumi T, Kuwano M, Leavitt BR, Singh SK, Jury A, Jones C, Wakimoto H, Reynolds BA, Pallen CJ, Dunn SE. YB-1 bridges neural stem cells and brain tumor-initiating cells via its roles in differentiation and cell growth. Cancer Res. 2011 Aug 15; 71(16):5569-78. PMID: 21730024.
    Citations: 27     Fields:    Translation:AnimalsCells
  103. Kanai R, Wakimoto H, Martuza RL, Rabkin SD. A novel oncolytic herpes simplex virus that synergizes with phosphoinositide 3-kinase/Akt pathway inhibitors to target glioblastoma stem cells. Clin Cancer Res. 2011 Jun 01; 17(11):3686-96. PMID: 21505062.
    Citations: 41     Fields:    Translation:AnimalsCells
  104. Bagci-Onder T, Wakimoto H, Anderegg M, Cameron C, Shah K. A dual PI3K/mTOR inhibitor, PI-103, cooperates with stem cell-delivered TRAIL in experimental glioma models. Cancer Res. 2011 Jan 01; 71(1):154-63. PMID: 21084267.
    Citations: 53     Fields:    Translation:HumansAnimalsCells
  105. Tamura K, Aoyagi M, Wakimoto H, Ando N, Nariai T, Yamamoto M, Ohno K. Accumulation of CD133-positive glioma cells after high-dose irradiation by Gamma Knife surgery plus external beam radiation. J Neurosurg. 2010 Aug; 113(2):310-8. PMID: 20205512.
    Citations: 48     Fields:    Translation:Humans
  106. Mikheeva SA, Mikheev AM, Petit A, Beyer R, Oxford RG, Khorasani L, Maxwell JP, Glackin CA, Wakimoto H, González-Herrero I, Sánchez-García I, Silber JR, Horner PJ, Rostomily RC. TWIST1 promotes invasion through mesenchymal change in human glioblastoma. Mol Cancer. 2010 Jul 20; 9:194. PMID: 20646316.
    Citations: 137     Fields:    Translation:HumansCells
  107. Passer BJ, Cheema T, Zhou B, Wakimoto H, Zaupa C, Razmjoo M, Sarte J, Wu S, Wu CL, Noah JW, Li Q, Buolamwini JK, Yen Y, Rabkin SD, Martuza RL. Identification of the ENT1 antagonists dipyridamole and dilazep as amplifiers of oncolytic herpes simplex virus-1 replication. Cancer Res. 2010 May 15; 70(10):3890-5. PMID: 20424118.
    Citations: 21     Fields:    Translation:HumansAnimalsCells
  108. Kanai R, Wakimoto H, Cheema T, Rabkin SD. Oncolytic herpes simplex virus vectors and chemotherapy: are combinatorial strategies more effective for cancer? Future Oncol. 2010 Apr; 6(4):619-34. PMID: 20373873.
    Citations: 26     Fields:    Translation:HumansCells
  109. Maguire CA, Gianni D, Meijer DH, Shaket LA, Wakimoto H, Rabkin SD, Gao G, Sena-Esteves M. Directed evolution of adeno-associated virus for glioma cell transduction. J Neurooncol. 2010 Feb; 96(3):337-47. PMID: 19618115.
    Citations: 21     Fields:    Translation:HumansCells
  110. Akaza M, Tsunemi T, Sanjo N, Wakimoto H, Kobayashi D, Mizusawa H. [Malignant lymphoma presented as left trigeminal neuralgia]. Rinsho Shinkeigaku. 2009 Jul; 49(7):432-6. PMID: 19715173.
    Citations: 1     Fields:    Translation:Humans
  111. Wakimoto H, Kesari S, Farrell CJ, Curry WT, Zaupa C, Aghi M, Kuroda T, Stemmer-Rachamimov A, Shah K, Liu TC, Jeyaretna DS, Debasitis J, Pruszak J, Martuza RL, Rabkin SD. Human glioblastoma-derived cancer stem cells: establishment of invasive glioma models and treatment with oncolytic herpes simplex virus vectors. Cancer Res. 2009 Apr 15; 69(8):3472-81. PMID: 19351838.
    Citations: 188     Fields:    Translation:HumansAnimalsCells
  112. Sasportas LS, Kasmieh R, Wakimoto H, Hingtgen S, van de Water JA, Mohapatra G, Figueiredo JL, Martuza RL, Weissleder R, Shah K. Assessment of therapeutic efficacy and fate of engineered human mesenchymal stem cells for cancer therapy. Proc Natl Acad Sci U S A. 2009 Mar 24; 106(12):4822-7. PMID: 19264968.
    Citations: 189     Fields:    Translation:HumansAnimalsCells
  113. Liu TC, Wakimoto H, Martuza RL, Rabkin SD. Herpes simplex virus Us3(-) mutant as oncolytic strategy and synergizes with phosphatidylinositol 3-kinase-Akt targeting molecular therapeutics. Clin Cancer Res. 2007 Oct 01; 13(19):5897-902. PMID: 17908985.
    Citations: 21     Fields:    Translation:HumansAnimalsCells
  114. Terada K, Wakimoto H, Wakimoto H, Tyminski E, Chiocca EA, Saeki Y. Development of a rapid method to generate multiple oncolytic HSV vectors and their in vivo evaluation using syngeneic mouse tumor models. Gene Ther. 2006 Apr; 13(8):705-14. PMID: 16421599.
    Citations: 54     Fields:    Translation:HumansAnimalsCells
  115. Tamura K, Aoyagi M, Wakimoto H, Tamaki M, Yamamoto K, Yamamoto M, Ohno K. Malignant transformation eight years after removal of a benign epidermoid cyst: a case report. J Neurooncol. 2006 Aug; 79(1):67-72. PMID: 16583265.
    Citations: 13     Fields:    Translation:Humans
  116. Nariai T, Tanaka Y, Wakimoto H, Aoyagi M, Tamaki M, Ishiwata K, Senda M, Ishii K, Hirakawa K, Ohno K. Usefulness of L-[methyl-11C] methionine-positron emission tomography as a biological monitoring tool in the treatment of glioma. J Neurosurg. 2005 Sep; 103(3):498-507. PMID: 16235683.
    Citations: 57     Fields:    Translation:HumansCTClinical Trials
  117. Nestler U, Wakimoto H, Siller-Lopez F, Aguilar LK, Chakravarti A, Muzikansky A, Stemmer-Rachamimov A, Chiocca EA, Aguilar-Cordova E, Hochberg FH. The combination of adenoviral HSV TK gene therapy and radiation is effective in athymic mouse glioblastoma xenografts without increasing toxic side effects. J Neurooncol. 2004 Mar-Apr; 67(1-2):177-88. PMID: 15072465.
    Citations: 12     Fields:    Translation:HumansAnimalsCells
  118. Duan L, Aoyagi M, Tamaki M, Yoshino Y, Morimoto T, Wakimoto H, Nagasaka Y, Hirakawa K, Ohno K, Yamamoto K. Impairment of both apoptotic and cytoprotective signalings in glioma cells resistant to the combined use of cisplatin and tumor necrosis factor alpha. Clin Cancer Res. 2004 Jan 01; 10(1 Pt 1):234-43. PMID: 14734475.
    Citations: 3     Fields:    Translation:HumansCells
  119. Wakimoto H, Wakimoto H, Fulci G, Tyminski E, Chiocca EA. Altered expression of antiviral cytokine mRNAs associated with cyclophosphamide's enhancement of viral oncolysis. Gene Ther. 2004 Jan; 11(2):214-23. PMID: 14712306.
    Citations: 56     Fields:    Translation:AnimalsCells
  120. Deisboeck TS, Wakimoto H, Wakimoto H, Nestler U, Louis DN, Sehgal PK, Simon M, Chiocca EA, Hochberg FH. Development of a novel non-human primate model for preclinical gene vector safety studies. Determining the effects of intracerebral HSV-1 inoculation in the common marmoset: a comparative study. Gene Ther. 2003 Aug; 10(15):1225-33. PMID: 12858187.
    Citations: 5     Fields:    Translation:AnimalsCells
  121. Wakimoto H, Wakimoto H, Johnson PR, Knipe DM, Chiocca EA. Effects of innate immunity on herpes simplex virus and its ability to kill tumor cells. Gene Ther. 2003 Jun; 10(11):983-90. PMID: 12756419.
    Citations: 40     Fields:    Translation:HumansAnimalsCells
  122. Abe T, Terada K, Wakimoto H, Inoue R, Tyminski E, Bookstein R, Basilion JP, Chiocca EA. PTEN decreases in vivo vascularization of experimental gliomas in spite of proangiogenic stimuli. Cancer Res. 2003 May 01; 63(9):2300-5. PMID: 12727853.
    Citations: 21     Fields:    Translation:HumansAnimalsCells
  123. Abe T, Wakimoto H, Bookstein R, Maneval DC, Chiocca EA, Basilion JP. Intra-arterial delivery of p53-containing adenoviral vector into experimental brain tumors. Cancer Gene Ther. 2002 Mar; 9(3):228-35. PMID: 11896438.
    Citations: 14     Fields:    Translation:HumansAnimalsCells
  124. Wakimoto H, Ikeda K, Abe T, Ichikawa T, Hochberg FH, Ezekowitz RA, Pasternack MS, Chiocca EA. The complement response against an oncolytic virus is species-specific in its activation pathways. Mol Ther. 2002 Mar; 5(3):275-82. PMID: 11863417.
    Citations: 35     Fields:    Translation:HumansAnimalsCells
  125. Huang X, Zhang W, Wakimoto H, Hamada H, Cao X. Adenovirus-mediated tissue-specific cytosine deaminase gene therapy for human hepatocellular carcinoma with different AFP expression levels. J Exp Ther Oncol. 2002 Mar-Apr; 2(2):100-6. PMID: 12415626.
    Citations:    Fields:    Translation:HumansAnimalsCells
  126. Tanaka M, Berul CI, Ishii M, Jay PY, Wakimoto H, Wakimoto H, Douglas P, Yamasaki N, Kawamoto T, Gehrmann J, Maguire CT, Schinke M, Seidman CE, Seidman JG, Kurachi Y, Izumo S. A mouse model of congenital heart disease: cardiac arrhythmias and atrial septal defect caused by haploinsufficiency of the cardiac transcription factor Csx/Nkx2.5. Cold Spring Harb Symp Quant Biol. 2002; 67:317-25. PMID: 12858555.
    Citations: 24     Fields:    Translation:HumansAnimalsCells
  127. Wakimoto H, Wakimoto H, Maguire CT, Kovoor P, Hammer PE, Gehrmann J, Triedman JK, Berul CI. Induction of atrial tachycardia and fibrillation in the mouse heart. Cardiovasc Res. 2001 Jun; 50(3):463-73. PMID: 11376622.
    Citations: 24     Fields:    Translation:Animals
  128. Nagashima G, Aoyagi M, Yamamoto S, Wakimoto H, Wakimoto H, Tamaki M, Yamamoto K, Fujimoto T, Hirakawa K. Involvement of disregulated c-myc but not c-sis/PDGF in atypical and anaplastic meningiomas. Clin Neurol Neurosurg. 2001 Apr; 103(1):13-8. PMID: 11311470.
    Citations: 1     Fields:    Translation:Humans
  129. Ikeda K, Wakimoto H, Wakimoto H, Ichikawa T, Jhung S, Hochberg FH, Louis DN, Chiocca EA. Complement depletion facilitates the infection of multiple brain tumors by an intravascular, replication-conditional herpes simplex virus mutant. J Virol. 2000 May; 74(10):4765-75. PMID: 10775615.
    Citations: 67     Fields:    Translation:HumansAnimalsCells
  130. Ikeda K, Ichikawa T, Wakimoto H, Wakimoto H, Silver JS, Deisboeck TS, Finkelstein D, Harsh GR, Louis DN, Bartus RT, Hochberg FH, Chiocca EA. Oncolytic virus therapy of multiple tumors in the brain requires suppression of innate and elicited antiviral responses. Nat Med. 1999 Aug; 5(8):881-7. PMID: 10426310.
    Citations: 128     Fields:    Translation:HumansAnimalsCells
  131. Nagashima G, Aoyagi M, Yamamoto M, Yamamoto S, Wakimoto H, Wakimoto H, Ohno K, Yamamoto K, Hirakawa K. P53 overexpression and proliferative potential in malignant meningiomas. Acta Neurochir (Wien). 1999; 141(1):53-61; discussion 60-1. PMID: 10071687.
    Citations: 5     Fields:    Translation:Humans
  132. Hara M, Aoyagi M, Nagashima G, Wakimoto H, Wakimoto H, Mikami T, Yamamoto S, Tamaki M, Hirakawa K. Recurrence in meningeal hemangiopericytomas. Surg Neurol. 1998 Dec; 50(6):586-91. PMID: 9870821.
    Citations: 5     Fields:    Translation:Humans
  133. Takada Y, Ohno K, Wakimoto H, Wakimoto H, Hirakawa K. Treatment of intracranial abscess in the era of neuroimaging: an analysis of 13 consecutive cases. J Med Dent Sci. 1998 Jun; 45(2):69-76. PMID: 11186202.
    Citations:    Fields:    Translation:Humans
  134. Yamamoto K, Yamamoto M, Akazawa K, Tajima S, Wakimoto H, Aoyagi M. Decrease in elastin gene expression and protein synthesis in fibroblasts derived from cardinal ligaments of patients with prolapsus uteri. Cell Biol Int. 1997 Sep; 21(9):605-11. PMID: 9570896.
    Citations: 19     Fields:    Translation:HumansCells
  135. Yamamoto S, Wakimoto H, Aoyagi M, Hirakawa K, Hamada H. Modulation of motility and proliferation of glioma cells by hepatocyte growth factor. Jpn J Cancer Res. 1997 Jun; 88(6):564-77. PMID: 9263534.
    Citations: 8     Fields:    Translation:HumansCells
  136. Wakimoto H, Yoshida Y, Aoyagi M, Hirakawa K, Hamada H. Efficient retrovirus-mediated cytokine-gene transduction of primary-cultured human glioma cells for tumor vaccination therapy. Jpn J Cancer Res. 1997 Mar; 88(3):296-305. PMID: 9140115.
    Citations: 4     Fields:    Translation:HumansCells
  137. Kanai F, Lan KH, Shiratori Y, Tanaka T, Ohashi M, Okudaira T, Yoshida Y, Wakimoto H, Wakimoto H, Hamada H, Nakabayashi H, Tamaoki T, Omata M. In vivo gene therapy for alpha-fetoprotein-producing hepatocellular carcinoma by adenovirus-mediated transfer of cytosine deaminase gene. Cancer Res. 1997 Feb 01; 57(3):461-5. PMID: 9012474.
    Citations: 25     Fields:    Translation:HumansAnimalsCells
  138. Lan KH, Kanai F, Shiratori Y, Okabe S, Yoshida Y, Wakimoto H, Hamada H, Tanaka T, Ohashi M, Omata M. Tumor-specific gene expression in carcinoembryonic antigen--producing gastric cancer cells using adenovirus vectors. Gastroenterology. 1996 Nov; 111(5):1241-51. PMID: 8898638.
    Citations: 6     Fields:    Translation:HumansCells
  139. Sato Y, Koshita Y, Hirayama M, Matuyama T, Wakimoto H, Hamada H, Nitsu Y. Augmented antitumor effects of killer cells induced by tumor necrosis factor gene-transduced autologous tumor cells from gastrointestinal cancer patients. Hum Gene Ther. 1996 Oct 01; 7(15):1895-905. PMID: 8894681.
    Citations: 1     Fields:    Translation:HumansCells
  140. Kato K, Shimozato O, Hoshi K, Wakimoto H, Hamada H, Yagita H, Okumura K. Local production of the p40 subunit of interleukin 12 suppresses T-helper 1-mediated immune responses and prevents allogeneic myoblast rejection. Proc Natl Acad Sci U S A. 1996 Aug 20; 93(17):9085-9. PMID: 8799158.
    Citations: 16     Fields:    Translation:AnimalsCells
  141. Kanai F, Shiratori Y, Yoshida Y, Wakimoto H, Hamada H, Kanegae Y, Saito I, Nakabayashi H, Tamaoki T, Tanaka T, Lan KH, Kato N, Shiina S, Omata M. Gene therapy for alpha-fetoprotein-producing human hepatoma cells by adenovirus-mediated transfer of the herpes simplex virus thymidine kinase gene. Hepatology. 1996 Jun; 23(6):1359-68. PMID: 8675152.
    Citations: 19     Fields:    Translation:HumansCells
  142. Wakimoto H, Abe J, Tsunoda R, Aoyagi M, Hirakawa K, Hamada H. Intensified antitumor immunity by a cancer vaccine that produces granulocyte-macrophage colony-stimulating factor plus interleukin 4. Cancer Res. 1996 Apr 15; 56(8):1828-33. PMID: 8620500.
    Citations: 12     Fields:    Translation:HumansAnimalsCells
  143. Tanaka T, Kanai F, Okabe S, Yoshida Y, Wakimoto H, Wakimoto H, Hamada H, Shiratori Y, Lan K, Ishitobi M, Omata M. Adenovirus-mediated prodrug gene therapy for carcinoembryonic antigen-producing human gastric carcinoma cells in vitro. Cancer Res. 1996 Mar 15; 56(6):1341-5. PMID: 8640823.
    Citations: 19     Fields:    Translation:HumansCells
  144. Wakimoto H, Wakimoto H, Aoyagi M, Nakayama T, Nagashima G, Yamamoto S, Tamaki M, Hirakawa K. Prognostic significance of Ki-67 labeling indices obtained using MIB-1 monoclonal antibody in patients with supratentorial astrocytomas. Cancer. 1996 Jan 15; 77(2):373-80. PMID: 8625247.
    Citations: 46     Fields:    Translation:Humans
  145. Abe J, Wakimoto H, Tsunoda R, Okabe S, Yoshida Y, Aoyagi M, Hirakawa K, Hamada H. In vivo antitumor effect of cytotoxic T lymphocytes engineered to produce interferon-gamma by adenovirus-mediated genetic transduction. Biochem Biophys Res Commun. 1996 Jan 05; 218(1):164-70. PMID: 8573124.
    Citations: 1     Fields:    Translation:HumansAnimalsCells
  146. Aoyagi M, Yamamoto M, Wakimoto H, Wakimoto H, Azuma H, Hirakawa K, Yamamoto K. Immunohistochemical detection of Ki-67 in replicative smooth muscle cells of rabbit carotid arteries after balloon denudation. Stroke. 1995 Dec; 26(12):2328-31; discussion 2331-2. PMID: 7491659.
    Citations: 2     Fields:    Translation:Animals
  147. Wakimoto H, Hamada H. [Retrovirus vector]. Tanpakushitsu Kakusan Koso. 1995 Dec; 40(17):2508-13. PMID: 8584692.
    Citations:    Fields:    Translation:AnimalsCells
  148. Nagashima G, Aoyagi M, Wakimoto H, Wakimoto H, Tamaki M, Ohno K, Hirakawa K. Immunohistochemical detection of progesterone receptors and the correlation with Ki-67 labeling indices in paraffin-embedded sections of meningiomas. Neurosurgery. 1995 Sep; 37(3):478-82; discussion 483. PMID: 7501113.
    Citations: 10     Fields:    Translation:Humans
  149. Abe J, Wakimoto H, Aoyagi M, Hirakawa K, Hamada H. Cytokine-gene-modified tumor vaccination intensified by a streptococcal preparation OK-432. Cancer Immunol Immunother. 1995 Aug; 41(2):82-6. PMID: 7656273.
    Citations: 2     Fields:    Translation:Animals
  150. Yamaguchi S, Wakimoto H, Yoshida Y, Kanegae Y, Saito I, Aoyagi M, Hirakawa K, Amagasa T, Hamada H. Enhancement of retrovirus-mediated gene transduction efficiency by transient overexpression of the amphotropic receptor, GLVR-2. Nucleic Acids Res. 1995 Jun 11; 23(11):2080-1. PMID: 7596842.
    Citations: 5     Fields:    Translation:HumansCells
  151. Abe J, Wakimoto H, Wakimoto H, Yoshida Y, Aoyagi M, Hirakawa K, Hamada H. Antitumor effect induced by granulocyte/macrophage-colony-stimulating factor gene-modified tumor vaccination: comparison of adenovirus- and retrovirus-mediated genetic transduction. J Cancer Res Clin Oncol. 1995; 121(9-10):587-92. PMID: 7559742.
    Citations: 6     Fields:    Translation:AnimalsCellsPHPublic Health
  152. Nakamura Y, Wakimoto H, Abe J, Kanegae Y, Saito I, Aoyagi M, Hirakawa K, Hamada H. Adoptive immunotherapy with murine tumor-specific T lymphocytes engineered to secrete interleukin 2. Cancer Res. 1994 Nov 15; 54(22):5757-60. PMID: 7525049.
    Citations: 19     Fields:    Translation:AnimalsCells
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact contactcatalyst.harvard.edu. For faculty or fellow appointment updates and changes, please ask your appointing department to contact HMS. For fellow personal and demographic information, contact HMS Human Resources at human_resourceshms.harvard.edu. For faculty personal and demographic information, contact HMS Office for Faculty Affairs at facappthms.harvard.edu.
Wakimoto's Networks
Click the
buttons for more information and interactive visualizations!
Concepts (564)
Co-Authors (129)
Similar People (60)
Same Department 
Physical Neighbors
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.